Country: Canada
Language: English
Source: Health Canada
SULFAMETHOXAZOLE; TRIMETHOPRIM
JUNO PHARMACEUTICALS CORP.
J01EE01
SULFAMETHOXAZOLE AND TRIMETHOPRIM
80MG; 16MG
SOLUTION
SULFAMETHOXAZOLE 80MG; TRIMETHOPRIM 16MG
INTRAVENOUS
100
Prescription
Active ingredient group (AIG) number: 0208901005; AHFS:
APPROVED
2022-08-30
Page 1 of 41 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION, BP sulfamethoxazole (80 mg/mL) + trimethoprim (16 mg/mL) sterile solution for the preparation of intravenous infusions ANTIBACTERIAL AGENT Juno Pharmaceuticals Corp 402-2233 Argentia Road, Mississauga, ON, L5N 2X7 Control Number: 258006 Date of Preparation: August 18, 2022 Page 2 of 41 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................... Error! Bookmark not defined. TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics (2 months – 12 years of age) .............................................................. 5 1.2 Geriatrics ............................................................................................................ 5 2 CONTRAINDICATIONS ............................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..................................................... 6 4 DOSAGE AND ADMINISTRATION .............................................................................. 6 4.1 Dosing Considerations ........................................................................................ 6 4.2 Recommended Dose and Dosage Adjustment .................................................... 6 4.3 Reconstitution ..................................................................................................... 8 4.4 Administration ..................................................................................................... 9 5 OVERDOSAGE ............................................................................................................ 9 6 DOSAGE FORMS, STRE Read the complete document